Showing 6911-6920 of 8468 results for "".
- New Image-Guided Dermatology Therapy System Receives CE Mark in Europehttps://practicaldermatology.com/news/new-oncology-and-dermatology-device-approved-europe/2463232/Ultrasound tech manufacturer TOOsonix A/S announced that it has received EU Medical Device Regulation (MDR) CE certification for its image-guided dermatologic therapy system, System ONE-M™, according to a news release from the company. The device facilitates the treatment of common skin c
- Innovent Plans to Submit NDA in China for Plaque Psoriasis Treatment Picankibart Following Phase 3 Datahttps://practicaldermatology.com/news/innovent-plans-submit-nda-china-plaque-psoriasis-treatment-picankibart-following-phase-3-data/2463195/Innovent Biologics announced that picankibart (IBI112) has met all the primary endpoints and key secondary endpoints in the phase 3 registrational study (CLEAR-1) in Chinese subjects with moderate to severe plaque psoriasis. CLEAR-1 is global the first phase 3 registration study in IL-23p
- J&J Expands Atopic Dermatitis Pipeline with Yellow Jersey Therapeutics Acquisitionhttps://practicaldermatology.com/news/jj-expands-ad-pipeline-yellow-jersey-therapeutics-125-billion-acquisition/2463207/Johnson & Johnson (J&J) has announced its plan to acquire Yellow Jersey Therapeutics (a subsidiary of Numab Therapeutics) for $1.25 billion in cash, according to a news release. The acquisition includes the bispecific antibody NM26, which is currently advancing to phase 2 studies f
- Dermavant Publishes ADORING 1 & ADORING 2 Phase 3 Trial Results for Vtama Cream for ADhttps://practicaldermatology.com/news/dermavant-publishes-adoring-1-adoring-2-phase-3-trial-results-vtama-cream-ad/2463173/Dermavant Sciences announced that the data from ADORING 1 and ADORING 2 phase 3 trials of Vtama (tapinarof) cream 1% for adults and children 2 years of age and older with atopic dermatitis (AD) has been published in the Journal of the American Academy of Dermatology. Vtama cream i
- TODAY Show Feature Criticizes FDA on Sunscreenshttps://practicaldermatology.com/news/today-show-feature-criticizes-fda-sunscreens/2463127/The US Food and Drug Administration (FDA) is doing Americans a disservice by not approving many of the modern sunscreens that are commonly used in Europe, a representative from the Environmental Working Group (EWG) told the TODAY television show last week. “Currently, the US sunscreen mar
- Roflumilast Foam Aligns with Industry Standards for Seborrheic Dermatitis Care: Studyhttps://practicaldermatology.com/news/roflumilast-foam-aligns-industry-standards-sd-care-study/2463119/A recent study published in the Journal of Clinical and Aesthetic Dermatology supports the approved formulation of roflumilast foam, noting that its alignment with beauty industry standards and exclusion of harmful ingredients is important for the confidence of practitioners using the tr
- Johnson & Johnson Acquires Proteologix, Maker of Atopic Dermatitis Candidate, for $850 Millionhttps://practicaldermatology.com/news/johnson-johnson-acquires-proteologix-maker-atopic-dermatitis-candidate-850-million/2463090/Johnson & Johnson has entered into a definitive agreement to acquire biotech company Proteologix for $850 million in cash, with potential for an additional milestone payment. Proteologix’s portfolio includes PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to ente
- Dr. Jeanine Downie Discusses Fake Botox in TV Segmenthttps://practicaldermatology.com/news/dr-jeanine-downie-discusses-fake-botox-tv-segment/2463070/If public awareness is the key to combatting the counterfeit Botox problem that has been popping up around the country recently, then Jeanine B. Downie, MD, FAAD, took a big step May 13. Dr. Downie, an Editorial Board member for Practical Dermatology's sister publication Mode
- Study: Apremilast Efficacy Shows Efficacy in Psoriasishttps://practicaldermatology.com/news/study-apremilast-efficacy-shows-efficacy-psoriasis/2463053/Results from a recent analysis suggest promise for apremilast, which showed efficacy in the treatment of patients with moderate-to-severe psoriasis. Authors publishing in Acta Dermato-Venereologica focused on the impact on skin lesions, pruritus, and serum cytokine levels. The r
- Consensus Statement Raises Awareness of CTCLhttps://practicaldermatology.com/news/consensus-statement-raises-awareness-ctcl/2463052/Kyowa Kirin, Inc. announced the publication of a patient-focused global consensus statement developed in collaboration with patient advocacy groups, calling on all healthcare authorities, hospitals, and clinicians to undertake 12 specific actions to enhance awareness, diagnosis, care, and support